Natco's partner Alvogen to market generic Oseltamivir phosphate power for oral suspension

In US market

Natco Pharma announced that its marketing partner Alvogen has received the final approval and is the first to market the generic equivalent to Oseltamivir phosphate, 6 mg/ ml powder for oral suspension in the United States. In December 2016, Alvogen launched the first generic equivalent to oseltamivir phosphate capsules in the United States.

Powered by Capital Market - Live News